Onera Health, developer of a patch-based home sleep test, announced the formation of a medical advisory board ahead of SLEEP 2023, where the company will present two poster abstracts. The medical advisory board consists of Ludger Grote, MD, PhD, medical director of the Sleep Disorders Center at the Sahlgrenska University Hospital in Gothenburg, Sweden; David…
Sleep technology company REMware has signed an agreement with Side Health, a virtual-first chronic care management company, to provide sleep apnea testing services. The partnership will help Side Health meet the growing demand to detect and treat undiagnosed sleep apnea among its patients. “The 2023 data shows 26% of the US adult population ages 30…
Newborn babies who experience low levels of oxygen in their body tissues due to sleep apnea, for example, tend to develop respiratory problems and hypertension in adulthood, and these problems may persist for the rest of their lives. The study, published in Sleep, by scientists at Sao Paulo State University (UNESP) in Brazil shows that…
New research published in Sleep found that teens with greater variability in their sleep patterns have a higher risk for school-related problems. The study, which will be presented Tuesday, June 6, during SLEEP 2023 in Indianapolis, shows that the teens with greater night-to-night variability in the time they fell asleep were 42% more likely to…
Cortisol levels in late pregnancy can predict the sleep of infants, according to a new study to be presented at the SLEEP 2023 annual meeting. Results show that newborns with higher levels of cortisol in their hair samples took longer to fall asleep at 7 months of age. Neonatal hair cortisol is a measure of…
The low blood oxygen levels of obstructive sleep apnea (OSA) cause widespread changes in gene activity throughout the day, according to a new study published in PLOS Biology. The finding may lead to tools for earlier diagnosis and tracking of the disorder. The activity of many genes varies naturally throughout the day, partially in response…
By Catherine Coveney, Loughborough University and Eric L Hsu, University of South Australia From sleep trackers to wakefulness drugs, the 21st century has seen an influx of new technology that could radically alter the way we sleep. Many of these new technologies chase the dream of optimised slumber. They promise to help tailor our sleep…
A new study published in the Journal of Clinical Sleep Medicine highlights the effectiveness of Wesper, a portable sleep lab designed to diagnose and titrate sleep apnea and other sleep-related disorders. The study demonstrates that Wesper compares favorably with polysomnography (PSG), the gold standard, paving the way for improved diagnosis and management of sleep apnea.…
Jazz Pharmaceuticals will present seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy, at SLEEP 2023 in Indianapolis. Presentations include four posters featuring real-world data on Xywav (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, for the treatment of narcolepsy patients with cataplexy and/or…
Avadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz (sodium oxybate) for extended-release oral suspension and patient preference for a once-nightly oxybate in 12 abstracts at SLEEP 2023. Lumryz (previously known as FT218), is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy…